These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32638109)

  • 1. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
    Mantero V; Rigamonti A; Basilico P; Crespi M; Balgera R; Salmaggi A
    J Neurol; 2020 Dec; 267(12):3465-3466. PubMed ID: 32638109
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
    Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
    Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
    Carnero Contentti E; Correa J
    Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
    [No Abstract]   [Full Text] [Related]  

  • 4. Tocilizumab administration in a refractory case of COVID-19.
    Dastan F; Nadji SA; Saffaei A; Tabarsi P
    Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab.
    Araki M; Aranami T; Matsuoka T; Nakamura M; Miyake S; Yamamura T
    Mod Rheumatol; 2013 Jul; 23(4):827-31. PubMed ID: 22782533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
    Solis-García Del Pozo J; Galindo MF; Nava E; Jordán J
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7475-7484. PubMed ID: 32706087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder.
    Maillart E; Renaldo F; Papeix C; Deiva K; Bonheur J; Kwon T; Boespflug-Tanguy O; Germanaud D; Marignier R
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32098863
    [No Abstract]   [Full Text] [Related]  

  • 8. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Brownlee W; Bourdette D; Broadley S; Killestein J; Ciccarelli O
    Neurology; 2020 Jun; 94(22):949-952. PubMed ID: 32241953
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
    Rosso M; Saxena S; Chitnis T
    Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
    [No Abstract]   [Full Text] [Related]  

  • 11. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus shifts to antibody cocktails for COVID-19 cytokine storm.
    Harrison C
    Nat Biotechnol; 2020 Aug; 38(8):905-908. PubMed ID: 32760027
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.
    Barros PO; Cassano T; Hygino J; Ferreira TB; Centurião N; Kasahara TM; Andrade RM; Linhares UC; Andrade AF; Vasconcelos CC; Alvarenga R; Marignier R; Bento CA
    Clin Exp Immunol; 2016 Mar; 183(3):480-9. PubMed ID: 26472479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of tocilizumab, an antibody against interleukin-6 receptor, for the treatment of neuromyelitis optica].
    Yamamura T; Araki M
    Brain Nerve; 2014 Oct; 66(10):1159-65. PubMed ID: 25296870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of IL-6 signaling in neuromyelitis optica.
    Araki M
    Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.
    Xu CY; Lu SD; Ye X; Cao MY; Xu GD; Yu Q; Qian JX; Zeng G
    QJM; 2020 Aug; 113(8):569-572. PubMed ID: 32365207
    [No Abstract]   [Full Text] [Related]  

  • 17. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
    Perricone C; Conigliaro P; Ciccacci C; Marcucci E; Cafaro G; Bartoloni E; Perricone R; Novelli G; Borgiani P; Gerli R
    Clin Exp Rheumatol; 2020; 38(3):580. PubMed ID: 32452345
    [No Abstract]   [Full Text] [Related]  

  • 18. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
    Ledford H
    Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
    [No Abstract]   [Full Text] [Related]  

  • 19. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
    Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
    J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.